- Home
- NSPR
NSPR
InspireMD Inc.
as 07-26-2024 4:00pm EST
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
| Founded: | N/A | Country: | Israel |
| Employees: | N/A | City: | TEL AVIV |
| Market Cap: | 63.4M | IPO Year: | N/A |
| Target Price: | $4.50 | AVG Volume (30 days): | 16.2K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.81 - $3.85 | Next Earning Date: | 08-06-2024 |
| Revenue: | $6,477,000 | Revenue Growth: | 23.91% |
| Revenue Growth (this year): | 14.57% | Revenue Growth (next year): | 52.09% |
Stock Insider Trading Activity of InspireMD Inc. (NSPR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ROUBIN GARY S | NSPR | Director | Nov 30 '23 | Buy | $2.53 | 50,000 | $126,540.00 | 438,902 | SEC Form 4 |
Latest InspireMD Inc. News
NSPR Breaking Stock News: Dive into NSPR Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million
GlobeNewswire
2 months ago
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024
GlobeNewswire
2 months ago
InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update
Simply Wall St.
2 months ago
InspireMD Insider Ups Holding By 13% During Year
GlobeNewswire
3 months ago
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th
GlobeNewswire
4 months ago
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
Simply Wall St.
4 months ago
InspireMD's (NASDAQ:NSPR) investors will be pleased with their solid 110% return over the last year
GlobeNewswire
4 months ago
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
Compare NSPR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NSPR InspireMD Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.